Incidence and disease course of new-onset diabetes mellitus in breast and colorectal cancer patients undergoing chemotherapy: A prospective multicenter cohort study
| Autor: | Yongjun Cha, Keun Seok Lee, Sung Hoon Sim, Ji Yeon Baek, Seung Chul Heo, Sujeong Go, You Jin Lee, Sun-Young Kim, In Hae Park, Jungnam Joo, Min Kyong Moon, Eun Kyung Lee, Yul Hwangbo, Hyewon Lee, Bo-Kyung Koo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Colorectal cancer Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Antineoplastic Agents Breast Neoplasms Prediabetic State 03 medical and health sciences 0302 clinical medicine Endocrinology Breast cancer Risk Factors Diabetes mellitus Internal medicine Republic of Korea Internal Medicine medicine Humans 030212 general & internal medicine Prospective Studies business.industry Incidence (epidemiology) Incidence Hazard ratio Cancer General Medicine Middle Aged medicine.disease Impaired fasting glucose Prognosis Survival Rate Diabetes Mellitus Type 2 Hyperglycemia Disease Progression Female business Colorectal Neoplasms Cohort study |
| Zdroj: | Diabetes research and clinical practice. 174 |
| ISSN: | 1872-8227 |
| Popis: | Aims To investigate the incidence of and risk factors for new-onset type 2 diabetes mellitus (DM) developed during chemotherapy that included steroids in cancer patients without DM. Methods This multicenter, prospective, and observational cohort study enrolled 299 cancer patients without DM (aged > 18 years), planning 4–8 cycles of adjuvant chemotherapy. The endpoints were the incidence, remission rate, and independent determinants of new-onset DM during chemotherapy. Results Between April 2015 and March 2018, 270 subjects with colorectal cancer or breast cancer (mean age, 51.0 years) completed the follow up (mean 39 months). Of whom, 17 subjects (6.3%) developed DM within a median time of 90 days (range, 17–359 days). Male sex (hazard ratio [HR], 15.839; 95% confidence interval [CI], 2.004–125.20) and impaired fasting glucose (IFG) at baseline (HR, 8.307; CI, 1.826–37.786) were independent risk factors. Six months after chemotherapy completion, 11/17 subjects (64.7%) experienced DM remission, associated with a significantly higher C-peptide level at baseline (C-peptide levels, 1.3 ng/mL in subjects with remission and 0.9 ng/mL in subjects without remission, age- and sex-adjusted P = 0.007). Conclusions DM incidence was 6.3% in patients who received chemotherapy with dexamethasone. Close monitoring for hyperglycemia is recommended, especially for men with IFG. Trial registration: ClinicalTrials.gov (NCT03062072). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect